Media coverage about Genetic Technologies (NASDAQ:GENE) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genetic Technologies earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.0870463500119 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Genetic Technologies (NASDAQ GENE) remained flat at $$1.35 during mid-day trading on Friday. The stock had a trading volume of 96,748 shares, compared to its average volume of 187,816. Genetic Technologies has a 12-month low of $0.70 and a 12-month high of $2.05.

COPYRIGHT VIOLATION WARNING: “Genetic Technologies (GENE) Earns News Sentiment Rating of 0.24” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at

Genetic Technologies Company Profile

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Insider Buying and Selling by Quarter for Genetic Technologies (NASDAQ:GENE)

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with's FREE daily email newsletter.